

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.
百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

REDESIGNATION OF DIRECTOR

BeiGene, Ltd. (the “**Company**”) hereby announces that the board of directors of the Company (the “**Board**”) has redesignated Mr. Anthony C. Hooper (“**Mr. Hooper**”) as an independent non-executive director effective from April 17, 2023 (the “**Redesignation**”). Previously, Mr. Hooper was a non-executive director. Following the Redesignation, Mr. Hooper will remain a member of the Board, the audit committee and the nominating and corporate governance committee and the chairman of the commercial and medical affairs advisory committee of the Board.

Reasons for the Redesignation

As disclosed in the circular to shareholders dated November 29, 2019, in connection with the share purchase agreement entered into by the Company with Amgen Inc. (“**Amgen**”), a substantial shareholder of the Company at the time of this announcement, Amgen had a contractual right to designate a director to the Board of the Company and named Mr. Hooper as its designee. Mr. Hooper was elected as a director by shareholders on December 27, 2019 and he formally joined the Board in January 2020 as a non-executive director. In June 2022, Mr. Hooper was re-elected by shareholders as a director for a three-year term ending in 2025.

On January 30, 2023, Amgen relinquished its director designation right and Mr. Hooper ceased to be an Amgen director designee. In light of the above and the factors set out below, both the Board and the nominating and corporate governance committee of the Board consider that Mr. Hooper fulfils all of the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and is therefore an independent non-executive director. In particular, among others:

- (i) Amgen has not provided professional services to the Company in the past two years. In addition, Mr. Hooper has not been a director, partner, principal or an employee of Amgen for the past two years; and
- (ii) Mr. Hooper currently does not, and has not within one year immediately prior to the Redesignation had, a material interest in any principal business activity of or was involved in any material business dealings with the Company, its holding company or their respective subsidiaries or any core connected persons of the Company. Mr. Hooper provides consultancy services to Amgen but only in matters unrelated to the Company on an as-needed basis. Mr. Hooper does not have day-to-day operational duties at Amgen. Mr. Hooper and Amgen have a clear understanding that Amgen has no control or influence over Mr. Hooper in his capacity as a director of the Company, and Mr. Hooper is not financially dependent on the consultancy fee he receives from Amgen.

Mr. Hooper's extensive industry and leadership experience has brought, and continues to bring, expert advice and perspectives to the Board. Mr. Hooper's status, an independent non-executive director, will allow the Board great flexibility in deciding on the roles it asks Mr. Hooper to play in the Board and Board committees. Additionally, the Redesignation would further strengthen the Company's corporate governance and checks and balances among Board members. It would allow the Board to have an additional, independent expert view on matters the Company engages in and transactions the Company conducts, in particular connected transactions where independent directors' views are especially important. Notwithstanding that he had been designated as a non-executive director at the time of his appointment, Mr. Hooper has carried on his role and responsibilities on the Board as if he was an independent non-executive director.

Biographical information on Mr. Hooper

Mr. Anthony C. Hooper has served as a member of the Board since January 2020. Mr. Hooper retired from Amgen in January 2020, where he was Executive Vice President from September 2018 to January 2020, and Executive Vice President, Global Commercial Operations from 2011 to August 2018. From 2010 to 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and Intercontinental of Bristol Myers Squibb Company (BMS). From 2009 to 2010, Mr. Hooper was President, Americas of BMS. From 2004 to 2009, Mr. Hooper was President, U.S. Pharmaceuticals, Worldwide Pharmaceuticals Group, a division of BMS. Prior to that, Mr. Hooper held various senior leadership positions at BMS. Prior to joining BMS, Mr. Hooper was Assistant Vice President of Global Marketing for Wyeth Laboratories. Mr. Hooper earned law and MBA degrees from the University of South Africa in 1978 and 1988, respectively. Mr. Hooper serves on the board of MannKind Corporation, a company listed on Nasdaq (ticker symbol: MNKD). Mr. Hooper is a consultant to Amgen.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, April 18, 2023

As of the date of this announcement, the board of directors of the Company consists of Mr. John V. Oyler as chairman and executive director, Dr. Xiaodong Wang as non-executive director, and Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi as independent non-executive directors.